ARM Surges 15% to $256 on Nvidia Vera, but Trades at 100x Forward P/E

ARM Holdings delivered one of the week's most dramatic percentage gains, climbing to $256.59 on enthusiasm around Nvidia's Vera standalone CPU architecture and the implied licensing opportunity for ARM. Yet beneath the surface, a valuation debate is brewing that challenges the magnitude of the implied upside. Nvidia guided for approximately $20 billion in standalone Vera CPU revenue going forward, a meaningful new product line. The market promptly assigned outsized value to ARM on the assumption that the company would capture a large slice of that revenue through licensing and royalty fees. However, detailed analysis reveals that ARM likely captures only 2 to 5 percent of that Vera revenue via traditional intellectual-property licensing, while Nvidia retains the overwhelming majority as the designer and manufacturer.

The valuation disconnect is stark: ARM is trading at roughly 100 times forward price-to-earnings, while NVDA trades at 25 times forward earnings. This multiple divergence reflects either extreme optimism on ARM's ability to expand its royalty base beyond Vera, or a significant mispricing. Vera is indeed a confidence signal from Nvidia, one that proves the company can build world-class custom silicon in-house without relying on third-party ISA (instruction-set architecture) partners. But that same fact cuts both ways for ARM: it demonstrates that the most valuable player in chip design is willing to bypass ARM's licensing altogether when the scale justifies it. For years, ARM's value proposition rested on being indispensable to data-center chip designers; Vera erodes that narrative.

MomentumThe empirical fact that winners keep winning over the medium term. in the semiconductor complex has been real. AMD rallied 8 percent on the day, Broadcom and other fabless designers posted gains, and the SOX index surged. This reflects genuine demand visibility from hyperscalers and enterprises deploying AI. But ARM's run-up in particular warrants scrutiny. The company's Q1 revenue contributions and licensing traction are solid, yet the stock's two-week advance from $220 to $256 outpaced the fundamental news. Short covering on an already-crowded position may have amplified the move, with traders noting that shorts are 'trapped' and forced to buy at higher levels, pushing ARM closer to $300. Watch whether this momentum sustains on earnings or whether the valuation reversion begins.